FYERS
Home
/
Stocks
/
Profit Loss
/
Emcure Pharmaceuticals Profit & Loss

Emcure Pharmaceuticals Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
₹2580 Cr₹2470 Cr₹2363 Cr₹2270 Cr₹2101 Cr₹2116 Cr₹1963 Cr₹2002 Cr₹1815 Cr₹1771 Cr₹1668 Cr₹1663 Cr₹1556 Cr
₹2 Cr₹4 Cr₹2 Cr₹39 Cr₹4 Cr₹4 Cr₹4 Cr₹36 Cr₹23 Cr₹12 Cr₹16 Cr₹1 Cr₹15 Cr
₹2583 Cr₹2474 Cr₹2365 Cr₹2309 Cr₹2104 Cr₹2121 Cr₹1967 Cr₹2038 Cr₹1838 Cr₹1784 Cr₹1683 Cr₹1664 Cr₹1571 Cr
₹2157 Cr₹2096 Cr₹1975 Cr₹1935 Cr₹1783 Cr₹1811 Cr₹1705 Cr₹1718 Cr₹1572 Cr₹1551 Cr₹1445 Cr₹1404 Cr₹1328 Cr
₹535 Cr₹484 Cr₹495 Cr₹479 Cr₹420 Cr₹407 Cr₹359 Cr₹417 Cr₹360 Cr₹323 Cr₹323 Cr₹330 Cr₹311 Cr
₹32 Cr₹46 Cr₹38 Cr₹33 Cr₹27 Cr₹39 Cr₹32 Cr₹46 Cr₹59 Cr₹65 Cr₹61 Cr₹59 Cr₹52 Cr
₹394 Cr₹341 Cr₹314 Cr₹341 Cr₹291 Cr₹261 Cr₹230 Cr₹273 Cr₹207 Cr₹167 Cr₹171 Cr₹198 Cr₹191 Cr
₹292 Cr₹244 Cr₹231 Cr₹251 Cr₹215 Cr₹197 Cr₹156 Cr₹202 Cr₹153 Cr₹121 Cr₹120 Cr₹146 Cr₹141 Cr

Share Price Live Stats

Open (₹)1,980.00
Volume (₹)47,459.00
High (₹)1,991.40
Upper Circuit2,179.80
Low (₹)1,943.50
Lower Circuit1,783.60
Prev Close1,981.70
52W High (₹)2,100.70
Price1,953.10
52W Low (₹)1,260.00

Share Market Cap & Key Ratios Overview

M.Cap (₹)37584.50 Cr
Div. Yield (%)0.18
PE Ratio37.16
Debt to Equity0.24
Price to Book6.13
Book Value260.46
EPS (TTM)53.31
Face Value10.00
ROE (%)20.09

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
LUPINNSE
EMCURENSE
LTP
1W Low
1W High
Market cap (₹)
1849.9+12.6 (0.69%)
1832.20
1891.50
4,47,476Cr
9602+227 (2.42%)
9312.50
9740
2,54,764Cr
4928.5+88.5 (1.83%)
4848.50
5010
1,89,423Cr
1180.3+20.3 (1.75%)
1152.10
1190.60
1,16,658Cr
1399+4.5 (0.32%)
1364.50
1419
1,11,484Cr
2026.2+72.2 (3.69%)
1963.80
2055.30
1,09,943Cr
2500+199.3 (8.66%)
2303
2504.30
1,01,712Cr
1200.4+15.4 (1.30%)
1185
1222
1,01,005Cr
1716-18 (-1.04%)
1689.30
1740
99,253Cr
2100.7+17.7 (0.85%)
2080
2135
96,031Cr
1953.1-50.7 (-2.53%)
1943.50
2045
37,585Cr

Key Highlights of Emcure Pharmaceuticals Ltd’s P&L

In 2026-03-31, Emcure Pharmaceuticals Ltd reported total revenue of ₹9335.01Cr, compared with ₹7968.78Cr in 2025-03-31, reflecting Emcure Pharmaceuticals Ltd turnover.

Depreciation was ₹415.05Cr and finance costs were ₹143.67Cr in 2026-03-31

Profit Before Tax (PBT) has been ₹1287.14Cr in 2026-03-31 as compared to ₹971.35Cr in 2025-03-31.

Net Profit (PAT) was ₹924.36Cr in 2026-03-31 compared with ₹681.33Cr in 2025-03-31.

Earnings per share (EPS) were ₹48.76 in 2026-03-31, compared with ₹35.96 in 2025-03-31.